GlassScriptPhysician profile
Emily S Kenner
NPI 1225201858
$5,385.93
in general payments reported to CMS, 2019-2025
31 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $54.08 · 2021: $2,336 · 2022: $751 · 2023: $659 · 2024: $779 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853 · Education: $9.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.27 |
| Education | $9.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,189.92 | 2019-2023 | Krystexxa |
| Amgen INC. | $500.56 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Vifor Pharma, INC. | $425.54 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $316.65 | 2019-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $279.51 | 2022-2023 | Ultomiris |
| Travere Therapeutics, INC. | $239.63 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $235.90 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $188.64 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $134.09 | 2019-2024 | Rayaldee |
| Aurinia Pharma U.S., INC. | $118.60 | 2022-2024 | Lupkynis |
| Recordati_rare_diseases_inc. | $95.85 | 2022-2025 | Cystadrops, Panhematin |
| Novo Nordisk INC | $74.46 | 2021-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $67.76 | 2021-2025 | |
| Daiichi Sankyo INC. | $58.51 | 2019-2022 | |
| Leadiant Biosciences, INC. | $56.87 | 2024 | Cystaran |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $53.61 | 2022-2023 | Purified Cortrophin Gel |
| Glaxosmithkline, LLC. | $53.59 | 2019-2025 | Benlysta |
| Akebia Therapeutics INC | $43.23 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.69 | 2023 | Gattex |
| Alnylam Pharmaceuticals INC. | $25.22 | 2022 | |
| Eusa Pharma (US) LLC | $24.28 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.88 | 2024 | Jardiance |
| Covidien LP | $19.27 | 2019 | |
| Ardelyx, INC. | $16.91 | 2025 | Ibsrela |
| Baxter Healthcare | $16.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.30 | 2024 | |
| Mallinckrodt Enterprises LLC | $15.81 | 2019 | |
| Lilly USA, LLC | $14.25 | 2024 | Jardiance |
| Shire North American Group INC | $13.61 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $13.37 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Kenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.